8-K

                          UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8-K
                         CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


 Date of Report (Date of earliest event reported): May 14, 2003


                      US Biodefense, Inc.
             ---------------------------------------
       (Exact name of Registrant as specified in charter)


        Utah               000-31431            33-0052057
   -------------          -----------          ------------
  (State of Other         (Commission          (IRS Employer
    Jurisdiction         File Number)       Identification No.)
 of Incorporation)


     13674 E. Valley Blvd.
     City of Industry, CA                    91746
  ---------------------------              ----------
(Address of Principal Executive            (Zip Code)
           Offices)


Registrant's telephone number, including area code: (626) 961-8039

                         Piedmont, Inc.
                  1001 - 17th Street, Suite M
                      Costa Mesa, CA 92626
        ---------------------------------------------
 (Former Name or Former Address, if Changed Since Last Report)












                               -1-






     Item 4.  Changes in Registrant's Certifying Accountant

     On  May 27, 2003, the Company dismissed Banker & Co. as  its
principal certifying accountants.  None of the reports of  Banker
&  Co.  on the financial statements of the Company contained  any
adverse  opinion  or disclaimer of opinion, or was  qualified  or
modified as to uncertainty, audit scope or accounting principles,
nor  have  there  been  at  any time, disagreements  between  the
Company  and Banker & Co. on any matter of accounting  principles
or practices, financial statement disclosure or auditing scope or
procedure.

     During the Company's two most recent fiscal years and during
any subsequent interim periods preceding the date of termination,
there  were no disagreements with Banker & Co. on any  matter  of
accounting   principles   or   practices,   financial   statement
disclosure,    or    auditing   scope   or    procedure,    which
disagreement(s), if not resolved to Banker & Co.'s  satisfaction,
would  have  caused them to refer to the subject  matter  of  the
disagreement(s) in connection with their report; and  there  were
no  "reportable events" as defined in Item 304 (a)(1)(v)  of  the
Securities and Exchange Commission's Regulation S-K.

     The  Company has subsequently engaged Beckstead & Watts, LLP
as  its  independent  accountants  for  the  fiscal  year  ending
December  31, 2003.  During the most recent two fiscal years  and
during  the  subsequent  interim period ending  March  31,  2003,
neither  the  Company  nor  anyone  engaged  on  its  behalf  has
consulted  with Beckstead & Watts, LLP regarding: (i) either  the
application  of accounting principles to a specified transaction,
either  completed or proposed; or the type of audit opinion  that
might be rendered on the Company's financial statements; or  (ii)
any  matter  that  was either the subject of a  disagreement  (as
defined in Item 304(a)(1)(v) of Regulation S-K).

     The  Company has furnished Banker & Co. with a copy of  the
disclosures under this Item 4 and has requested that Banker & Co.
provide a letter addressed to the SEC stating whether or not they
agree  with the statements made herein or stating the reasons  in
which  they do not agree.  The letter from Banker & Co. is  filed
herewith.

Item 5.  Other Events and Regulation FD Disclosure

     The  Company has filed an amendment with the State  of  Utah
Department  of  Commerce to change the name of the  Company  from
Piedmont, Inc. to U.S. Biodefense, Inc.

     A  majority of the shareholders of the Company have  elected
to  effect a reverse stock split whereby one post-split share  of
the  Company's $0.001 par value common stock will be  issued  for
every  100 pre-split shares of the Company common stock  held  by
the shareholders of the Company.

     Additionally,  the  Company has  submitted  a  request  with
Nasdaq Market Integrity to change its ticker symbol

Item 6.  Resignations of Registrant's Directors

     The  Board  of  Directors has tendered the  resignations  of
Vincent  van den Brink, as President and Director of the Company,
and  Rita  Thomas, as Secretary, Treasurer and  Director  of  the
Company.

     David  Chin  has  been elected to serve  as  the  President,
Secretary, Treasurer and Director of the Company.






                               -2-





Item 7.  Exhibits

     99.1  Letter from Jitendra Shantikumar Banker, C.P.A.



                           Signatures

  Pursuant to the requirements of the Securities Exchange Act  of
1934, the registrant has duly caused this report to be signed  on
its behalf by the undersigned hereunto duly authorized.

     Signature               Title                  Date
     ---------               -----                  ----


   /s/ David Chin        President and          June 9, 2003
- --------------------       Director
     David Chin





























                               -3-

EX-99

June 3, 2003



United States Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W., Mail Stop 4-5
Washington, D.C. 20549

To Whom It May Concern:

We  have  read  Item  4 of Form 8-K dated May  27,  2003,  of  US
Biodefense  (formerly  known  as  Piedmont,  Inc.)  and  are   in
agreement  with the statements contained in Item 4  on  page  two
therein.   We  have  no  basis to agree or  disagree  with  other
statements of the registrant contained therein.


Sincerely,
Banker & Co.

/s/ Jitendra Shantikumar Banker
- ------------------------------------------------
Jitendra Shantikumar Banker, C.P.A.
(License No. 01696129)
Certified Public Accountant
Costa Mesa, California